Ceribell Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CeriBell, Inc. | ||
| Date: February 25, 2025 | By: | /s/ Xingjuan (Jane) Chao, Ph.D. |
|---|---|---|
| Xingjuan (Jane) Chao, Ph.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Xingjuan (Jane) Chao, Ph.D. and Scott Blumberg, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Xingjuan (Jane) Chao, Ph.D. | President, Chief Executive Officer, and Director | February 25, 2025 |
| Xingjuan (Jane) Chao, Ph.D. | (Principal Executive Officer) | |
| /s/ Scott Blumberg | Chief Financial Officer | February 25, 2025 |
| Scott Blumberg | (Principal Financial Officer) | |
| /s/ David Foehr | Senior Vice President, Finance | February 25, 2025 |
| David Foehr | (Principal Accounting Officer) | |
| /s/ Rebecca Robertson | Chair of the Board of Directors | February 25, 2025 |
| Rebecca Robertson | ||
| /s/ Juliet Tammenoms Bakker | Director | February 25, 2025 |
| Juliet Tammenoms Bakker | ||
| /s/ William W. Burke | Director | February 25, 2025 |
| William W. Burke | ||
| /s/ Lucian Iancovici, M.D. | Director | February 25, 2025 |
| Lucian Iancovici, M.D. | ||
| /s/ Josef Parvizi, M.D., Ph.D. | Director | February 25, 2025 |
| Josef Parvizi, M.D., Ph.D. | ||
| /s/ Joseph M. Taylor | Director | February 25, 2025 |
| Joseph M. Taylor | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.